Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.39 |
| ▸ | CPB1 | P15086 | 2/20 | 0.36 |
| ▸ | ACE | P12821 | 4/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 4/20 | 0.34 |
| ▸ | CPA1 | P15085 | 1/20 | 0.34 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.33 |
| ▸ | ECE1 | P42892 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5869297 | 1.00 | CPB2 (0.39) | CPB2CPB1ACECA2MME | |
| SCHEMBL8254294 | 0.95 | ACE (0.42) | CPB2CPB1ACENOD1FOLH1 | |
| SCHEMBL5869512 | 0.95 | ACE (0.42) | CPB2CPB1ACENOD1FOLH1 | |
| SCHEMBL8249067 | 0.92 | CPB2 (0.38) | CPB2CPB1ACEMME | |
| SCHEMBL8249911 | 0.92 | CPB2 (0.38) | CPB2CPB1ACEMME | |
| SCHEMBL5869764 | 0.92 | CPB2 (0.38) | CPB2CPB1ACEMME | |
| SCHEMBL11499160 | 0.89 | MME (0.40) | CPB2CPB1ACECA2MME | |
| SCHEMBL5964360 | 0.89 | CPB2 (0.39) | CPB2CPB1ACECA2MME | |
| SCHEMBL11499162 | 0.89 | MME (0.40) | CPB2CPB1ACECA2MME | |
| SCHEMBL5870309 | 0.87 | CPB2 (0.36) | CPB2CPB1ACECA2MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | CPB2 16/4885CPB1 67/4885ACE 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.